[Treatment of fetal hemolytic disease by hemosorption]

Hemosorption was used in the combined treatment of fetal hemolytic disease (FHD) for the first time. It was demonstrated that hemosorption was a method of choice in pregnant females with manifest sensitization and a history of stillbirth resulted from an edematous type of the disease. A decrease (by a factor of 10(2) to 10(6] in the Rh antibody titers in the blood of the pregnant after hemosorption, and reversibility of echocardiographic signs of FHD, and normalized fetal cardiac performance were regarded as a beneficial prognostic sign. The authors suggested that hemosorption should be started at weeks 24-25 of pregnancy in the absence of echographic signs of the disease. The interval between the sessions should not exceed a fortnight. The treatment course should be completed 1-2 weeks prior to the labor. As part of combined treatment, hemosorption contributed to a reduction in mortality rates (from 81 to 41%) from the edematous type of the disease.